Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) Antibodies:
anti-Rat (Rattus) Antibodies:
Go to our pre-filtered search.
Human Polyclonal AKR1B1 Primary Antibody for WB - ABIN513260
Hernández-Ochoa, Robison, Contreras, Shen, Zhao, Schneider: Elevated extracellular glucose and uncontrolled type 1 diabetes enhance NFAT5 signaling and disrupt the transverse tubular network in mouse skeletal muscle. in Experimental biology and medicine (Maywood, N.J.) 2012
Human Monoclonal AKR1B1 Primary Antibody for IHC (p), ELISA - ABIN513262
Ebert, Kisiela, Wsól, Maser: Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29. in Chemico-biological interactions 2011
Human Polyclonal AKR1B1 Primary Antibody for ICC, IF - ABIN4278953
Orton, Doucette, Maksym, MacLellan: Proteomic analysis of rat proximal tubule cells following stretch-induced apoptosis in an in vitro model of kidney obstruction. in Journal of proteomics 2014
Human Polyclonal AKR1B1 Primary Antibody for IHC, WB - ABIN4890159
Steuber, Heine, Podjarny, Klebe: Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features. in Journal of molecular biology 2008
Human Polyclonal AKR1B1 Primary Antibody for IF, IHC (p) - ABIN389205
Gleissner, Sanders, Nadler, Ley: Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. in Arteriosclerosis, thrombosis, and vascular biology 2008
Show all 3 Pubmed References
Structure of ALR1 in ternary complex with NADPH and 3,5-dichlorosalicylic acid is reported as well as the implications for inhibitor binding and selectivity.
L-idose is the best alternative to D-glucose in studies on aldose reductase.
prostaglandin F synthase (show AKR1C3 Antibodies) activity of human and bovine aldo-keto reductases
Aldehyde reductase exerts a protective effect against carbon tetrachloride-induced hepatic steatosis by replenishing ascorbic acid via its antioxidative properties.
Aldose reductase acts as a switch which can regulate microglia by polarizing cells after spinal cord injury.
Aldose reductase contributes to diabetes-mediated mitochondrial dysfunction and damage through the activation of p53 (show TP53 Antibodies).
Data indicate that inhibition of AR alleviates the MCD (show MLYCD Antibodies) diet-induced liver inflammation and fibrosis in db/db (show LEPR Antibodies) mice, probably through dampening CYP2E1 (show CYP2E1 Antibodies) mediated-oxidative stress and ameliorating the expression of pro-inflammatory cytokines.
FMHM suppressed the activity of AR-dependent phospholipase C (show PLC Antibodies)/protein kinase C (show PKC Antibodies) signaling, which further resulted in downstream inactivation of the IkappaB kinase (show CHUK Antibodies)/IkappaB/nuclear factor-kappa B inflammatory pathway.
Allergen-induced airway remodeling is mediated by AR and its inhibition blocks the progression of remodeling via inhibiting TGFbeta1 (show TGFB1 Antibodies)-induced Smad (show SMAD1 Antibodies)-independent and PI3K/AKT (show AKT1 Antibodies)/GSK3beta (show GSK3b Antibodies)-dependent pathway.
BGG-mediated inhibition of aldose reductase prevented LPS (show TLR4 Antibodies)-induced activation of JNK (show MAPK8 Antibodies).
The crystal structure of AKR1a4 in its apo (show C9orf3 Antibodies) form at high resolution.
crystal of AKR1B3 was tetragonal, belonging to space group P4(1)2(1)2 or P4(3)2(1)2, with unit-cell parameters a = b = 107.62, c = 120.76 A
the role of AKR1B3 in regulating advanced glycosylation end products and advanced lipoxidation end products
An meta-analysis showed that aldose reductase C-106T variants appear to influence the risk for diabetic retinopathy in Chinese Han persons (meta-analysis).
AKR1B1 as a key modulator of tumor aggressiveness and suggests that pharmacologic inhibition of AKR1B1 has the potential to become a valuable therapeutic strategy for Basal-like breast cancer (BLBC).
Result indicate that the differential scanning fluorimetry (DSF) method is useful for enzyme inhibitor drug screening for the AKR superfamily, including AKR1B10 (show AKR1B10 Antibodies) and a structurally similar isoform AKR1B1.
The hyperosmotic AR gene expression was dependent on activation of metalloproteinases, autocrine/paracrine TGF-beta (show TGFB1 Antibodies) signaling, activation of p38 MAPK (show MAPK14 Antibodies), ERK1/2 (show MAPK1/3 Antibodies), and PI3K (show PIK3CA Antibodies) signal transduction pathways, and the transcriptional activity of NFAT5 (show NFAT5 Antibodies).
Aberrant DNA methylation (show HELLS Antibodies) of AKR1B1 could be potential screening markers of colorectal cancer.
-106T allele of AKR1B1 C-106T polymorphism may be associated with increased risk for essential hypertension in Chinese Han population.
These findings suggest a statistically significant association of AKR1B1 -106C>T polymorphism with retinopathy in North Indian patients
ALR (show GFER Antibodies) C(-106)T polymorphism was not associated with an increased risk of Diabetic Retinopathy; subgroup analysis showed a genetic association between ALR (show GFER Antibodies) C(-106)T polymorphism and the risk of Diabetic Retinopathy of type 1 Diabetes but not Diabetic Retinopathy of type 2 Diabetes(Meta-Analysis)
Higher expression of PLA2G2A (show PLA2G2A Antibodies), PTGS2 (show PTGS2 Antibodies), AKR1B1, AKR1C3 (show AKR1C3 Antibodies) and ABCC4 (show ABCC4 Antibodies) was seen in 22-B endometriosis cells.
Data conclude that AKR1B1 and TM6SF1 may serve as candidate methylation biomarkers for early breast cancer detection.
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. This member catalyzes the reduction of a number of aldehydes, including the aldehyde form of glucose, and is thereby implicated in the development of diabetic complications by catalyzing the reduction of glucose to sorbitol. Multiple pseudogenes have been identified for this gene. The nomenclature system used by the HUGO Gene Nomenclature Committee to define human aldo-keto reductase family members is known to differ from that used by the Mouse Genome Informatics database.
aldo-keto reductase family 1, member B1-like
, aldose reductase
, aldo-keto reductase family 1, member B1 (aldose reductase)
, alcohol dehydrogenase
, alcohol dehydrogenase [NADP(+)]
, aldehyde reductase
, aldo-keto reductase family 1 member A1
, aldo-keto reductase family 1, member A4 (aldehyde reductase)
, 3-DG-reducing enzyme
, Lii5-2 CTCL tumor antigen
, aldehyde reductase 1
, aldo-keto reductase family 1 member B1
, low Km aldose reductase
, 20-alpha-hydroxysteroid dehydrogenase
, Aldehyde reductase 1 (low Km aldose reductase) (5.8 kb PstI fragment, probably the functional gene)
, aldo-keto reductase family 1, member B4 (aldose reductase)